Literature DB >> 25946396

Bipolar disorder prevalence: a systematic review and meta-analysis of the literature.

Adauto S Clemente1, Breno S Diniz2, Rodrigo Nicolato2, Flavio P Kapczinski3, Jair C Soares4, Josélia O Firmo1, Érico Castro-Costa1.   

Abstract

OBJECTIVE: Bipolar disorder (BD) is common in clinical psychiatric practice, and several studies have estimated its prevalence to range from 0.5 to 5% in community-based samples. However, no systematic review and meta-analysis of the prevalence of BD type 1 and type 2 has been published in the literature. We carried out a systematic review and meta-analysis of the lifetime and 1-year prevalence of BD type 1 and type 2 and assessed whether the prevalence of BD changed according to the diagnostic criteria adopted (DSM-III, DSM-III-R vs. DSM-IV).
METHODS: We searched MEDLINE, Scopus, Web of Science, PsycINFO, and the reference lists of identified studies. The analyses included 25 population- or community-based studies and 276,221 participants.
RESULTS: The pooled lifetime prevalence of BD type 1 was 1.06% (95% confidence interval [95%CI] 0.81-1.31) and that of BD type 2 was 1.57% (95%CI 1.15-1.99). The pooled 1-year prevalence was 0.71% (95%CI 0.56-0.86) for BD type 1 and 0.50% (95%CI 0.35-0.64) for BD type 2. Subgroup analysis showed a significantly higher lifetime prevalence of BD type 1 according to the DSM-IV criteria compared to the DSM-III and DSM-IIIR criteria (p < 0.001).
CONCLUSION: This meta-analysis confirms that estimates of BD type 1 and type 2 prevalence are low in the general population. The increase in prevalence from DSM-III and DSM-III-R to DSM-IV may reflect different factors, such as minor changes in diagnostic operationalization, use of different assessment instruments, or even a genuine increase in the prevalence of BD.

Entities:  

Mesh:

Year:  2015        PMID: 25946396     DOI: 10.1590/1516-4446-2012-1693

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  29 in total

1.  Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III.

Authors:  Carlos Blanco; Wilson M Compton; Tulshi D Saha; Benjamin I Goldstein; W June Ruan; Boji Huang; Bridget F Grant
Journal:  J Psychiatr Res       Date:  2016-10-07       Impact factor: 4.791

Review 2.  History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis.

Authors:  Breno S Diniz; Antonio L Teixeira; Fei Cao; Ariel Gildengers; Jair C Soares; Meryl A Butters; Charles F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  2017-01-04       Impact factor: 4.105

Review 3.  Epidemiology and risk factors for bipolar disorder.

Authors:  Tobias A Rowland; Steven Marwaha
Journal:  Ther Adv Psychopharmacol       Date:  2018-04-26

Review 4.  Psychiatric disease as a risk factor in fast-track hip and knee replacement.

Authors:  Silas Hinsch Gylvin; Christoffer Calov Jørgensen; Anders Fink-Jensen; Henrik Kehlet
Journal:  Acta Orthop       Date:  2016-02-22       Impact factor: 3.717

5.  Association of Alzhemier's disease with hepatitis C among patients with bipolar disorder.

Authors:  Herng-Ching Lin; Sudha Xirasagar; Hsin-Chien Lee; Chung-Chien Huang; Chao-Hung Chen
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

Review 6.  Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review.

Authors:  Xin Yu; Christoph U Correll; Yu-Tao Xiang; Yifeng Xu; Jizhong Huang; Fude Yang; Gang Wang; Tianmei Si; John M Kane; Prakash Masand
Journal:  Shanghai Arch Psychiatry       Date:  2016-10-25

7.  Duration of untreated bipolar disorder: a multicenter study.

Authors:  Ling Zhang; Xin Yu; Yi-Ru Fang; Gabor S Ungvari; Chee H Ng; Helen F K Chiu; Hui-Chun Li; Hai-Chen Yang; Qing-Rong Tan; Xiu-Feng Xu; Gang Wang; Yu-Tao Xiang
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

8.  Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study).

Authors:  Lumbini Azim; Paul Hindmarch; Georgiana Browne; Thomas Chadwick; Emily Clare; Paul Courtney; Lyndsey Dixon; Nichola Duffelen; Tony Fouweather; John R Geddes; Nicola Goudie; Sandy Harvey; Timea Helter; Eva-Maria Holstein; Garry Martin; Phil Mawson; Jenny McCaffery; Richard Morriss; Judit Simon; Daniel Smith; Paul R A Stokes; Jenn Walker; Chris Weetman; Faye Wolstenhulme; Allan H Young; Stuart Watson; R Hamish McAllister-Williams
Journal:  BMC Psychiatry       Date:  2021-07-05       Impact factor: 3.630

Review 9.  Big data for bipolar disorder.

Authors:  Scott Monteith; Tasha Glenn; John Geddes; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2016-04-11

Review 10.  Mixed States in Bipolar Disorder: Etiology, Pathogenesis and Treatment.

Authors:  Ather Muneer
Journal:  Chonnam Med J       Date:  2017-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.